By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. (0HKF.L)

LSE Currency in USD
$110.70
-$1.87
-1.66%
Last Update: 16 Jul 2025, 16:19
$5.45B
Market Cap
-19.12
P/E Ratio (TTM)
Forward Dividend Yield
$55.64 - $111.53
52 Week Range

0HKF.L Stock Price Chart

Explore Axsome Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0HKF.L price movements and trends.

There is nothing to show.

0HKF.L Company Profile

Discover essential business fundamentals and corporate details for Axsome Therapeutics, Inc. (0HKF.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

IPO Date

29 Jan 2018

Employees

712.00

CEO

Herriot Tabuteau

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

0HKF.L Financial Timeline

Browse a chronological timeline of Axsome Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 4 May 2026

Upcoming earnings on 16 Feb 2026

Upcoming earnings on 10 Nov 2025

Upcoming earnings on 4 Aug 2025

Revenue estimate is $140.02M.

Earnings released on 5 May 2025

EPS came in at -$1.22 surpassing the estimated -$1.35 by +9.71%, while revenue for the quarter reached $121.46M, missing expectations by -13.51%.

Earnings released on 18 Feb 2025

EPS came in at -$1.54 falling short of the estimated -$1.00 by -54.17%, while revenue for the quarter reached $118.77M, missing expectations by -0.62%.

Earnings released on 12 Nov 2024

EPS came in at -$1.34 surpassing the estimated -$1.38 by +3.14%, while revenue for the quarter reached $103.74M, missing expectations by -12.04%.

Earnings released on 5 Aug 2024

EPS came in at -$1.67 falling short of the estimated -$1.31 by -27.59%, while revenue for the quarter reached $87.17M, beating expectations by +0.28%.

Earnings released on 6 May 2024

EPS came in at -$1.44 falling short of the estimated -$1.20 by -19.74%, while revenue for the quarter reached $75.00M, beating expectations by +2.33%.

Earnings released on 6 Mar 2024

EPS came in at -$2.08 falling short of the estimated -$1.17 by -77.94%, while revenue for the quarter reached $71.53M, beating expectations by +3.31%.

Earnings released on 6 Nov 2023

EPS came in at -$1.32 falling short of the estimated -$1.20 by -9.71%, while revenue for the quarter reached $57.79M, beating expectations by +5.33%.

Earnings released on 7 Aug 2023

EPS came in at -$1.54 falling short of the estimated -$1.21 by -26.75%, while revenue for the quarter reached $46.70M, beating expectations by +14.24%.

Earnings released on 8 May 2023

EPS came in at -$0.26 surpassing the estimated -$1.30 by +80.23%, while revenue for the quarter reached $94.58M, beating expectations by +271.31%.

Earnings released on 27 Feb 2023

EPS came in at -$1.41 falling short of the estimated -$1.13 by -25.19%, while revenue for the quarter reached $24.37M, beating expectations by +12.03%.

Earnings released on 30 Sept 2022

EPS came in at -$1.07 falling short of the estimated -$1.05 by -2.35%, while revenue for the quarter reached $16.85M, beating expectations by +1.26%.

Earnings released on 30 Jun 2022

EPS came in at -$1.06 falling short of the estimated -$1.01 by -5.39%, while revenue for the quarter reached $8.82M, beating expectations by +27.49%.

Earnings released on 31 Mar 2022

EPS came in at -$1.03 falling short of the estimated -$1.00 by -3.13%.

Earnings released on 31 Dec 2021

EPS came in at -$0.90.

Earnings released on 30 Sept 2021

EPS came in at -$0.93 surpassing the estimated -$1.02 by +9.38%.

Earnings released on 30 Jun 2021

EPS came in at -$0.86.

Earnings released on 31 Mar 2021

EPS came in at -$0.78.

Earnings released on 31 Dec 2020

EPS came in at -$0.78.

Earnings released on 30 Sept 2020

EPS came in at -$0.61.

0HKF.L Stock Performance

Access detailed 0HKF.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
0HKF.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
0HKF.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More